Q1 Media Minds Roundtable Panel – What Will 2026 Look Like for Biotech and Healthcare? Post-JPM Journalist Perspectives

​Annalee Armstrong is an award-winning biopharma journalist covering the business of drug development. She began her career at small newspapers across Western Canada. During the assignment of a lifetime, the Yukon Quest Sled Dog Race, she met her husband in Alaska and eventually moved to the U.S. Since then, Annalee has covered energy, environmental regulations, healthcare and biopharma. Prior to BioSpace, Annalee was senior editor for Fierce Biotech, where she received several awards for her writing and editing. She lives in Ottawa, Ontario, with her husband, two wild boys, an anxious Rhodesian Ridgeback and an indifferent tabby cat.

​Max Bayer is a senior reporter at Endpoints News. He joined from Fierce Biotech where he spent more than two years reporting on all corners of the biotech industry. He previously spent more than three years at CBS News, covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. A Bay Area native, Max graduated from the University of Wisconsin-Madison in 2018 and now lives in Brooklyn, rooting on northern California sports teams and biking around the borough (with a helmet, of course).

​Mandy Jackson reports on daily biopharma developments, writes feature stories and produces Scrip’s Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.